+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 25 Actively Recruiting clinical trials

R

Actively Recruiting

Researchers are evaluating a new medication called CX11 for people with type 2 diabetes who have not achieved good blood sugar control despite taking a steady dose of metformin, with or without an SGLT2 inhibitor, for at least 90 days. This phase 2 study involves multiple medical centers and aims to determine the effectiveness and safety of CX11 compared to placebo in adults aged 18 to 75 years with specific blood sugar and body weight criteria. Participants will be randomly assigned to one of six groups, each receiving either a different dose of CX11 tablets or a matching placebo once daily. The treatment period lasts 24 weeks, followed by a 2-week safety follow-up. Neither participants nor study staff will know which group the participant is in during the study, ensuring a double-blind design. Throughout the study, participants will undergo various assessments including blood sugar measurements like HbA1c and continuous glucose monitoring, body weight and blood pressure checks, and safety monitoring for adverse events. Blood samples will be taken at multiple time points to measure drug levels. The primary outcome is the change in HbA1c after 24 weeks of treatment. Total participation lasts approximately 26 weeks, including treatment and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
48 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating an investigational mRNA seasonal flu vaccine compared to a licensed flu vaccine in adults aged 65 years and older. The study aims to assess the ability of the vaccines to prevent laboratory-confirmed influenza illness, monitor side effects, and measure immune responses during the flu season. This Phase 3 randomized, observer-blind trial is sponsored by GlaxoSmithKline and focuses on flu prevention in older adults. Participants will receive a single injection on Day 1 of either the investigational mRNA seasonal flu vaccine or a licensed, age-appropriate, season-adapted influenza vaccine. The study follows a parallel group design where participants are randomly assigned to one of these two vaccine groups. The follow-up period covers the entire influenza season to assess vaccine efficacy and safety. During the study, participants will be monitored for influenza-like illness confirmed by laboratory tests from Day 15 through the end of the influenza season. Safety assessments include tracking solicited local and systemic side effects from Day 1 to Day 7, unsolicited adverse events up to Day 28, and serious adverse events or special interest adverse events through at least 180 days of follow-up. Blood samples will be collected before dosing and on Day 29 to evaluate immune responses. Participants are followed for safety and efficacy throughout the flu season, with total involvement spanning several months.

Age: 65Years +All GendersPhase 3
163 locations
R

Actively Recruiting

Researchers are studying adults with treatment-resistant depression TRD to evaluate the effects of ALTO-207 compared with a placebo. This clinical trial aims to measure changes in depressive symptoms, particularly focusing on the Montgomery-sberg Depression Rating Scale MADRS scores over eight weeks. The study is randomized, double-blind, and placebo-controlled, conducted by Alto Neuroscience. Participants receive either ALTO-207 or a matching placebo twice daily BID during the treatment phase. The trial follows a parallel design, comparing the effects of the experimental drug to placebo over the course of the study. Throughout the trial, participants undergo assessments including changes in MADRS scores and clinician-administered Clinical Global Impression-Severity CGI-S scores. The primary outcome is the change from baseline in MADRS total score up to eight weeks. Secondary outcomes include response rates and CGI-S score changes. Safety and adherence are monitored, with a total participation period extending through the eight-week treatment phase and follow-up.

Age: 18Years - 75YearsAll GendersPhase 2
63 locations
C

Actively Recruiting

Researchers are evaluating how well zenagamtide works and how safe it is compared to insulin glargine in people with type 2 diabetes who have a higher risk of heart and blood vessel problems. This study includes participants already taking 1 to 3 diabetes medications and aims to see if zenagamtide is not worse than insulin glargine in controlling blood sugar levels over one year. Participants are randomly assigned to receive either zenagamtide or insulin glargine. Zenagamtide is given once weekly as an injection under the skin in the thigh, abdomen, or upper arm using a pre-filled pen injector. Insulin glargine is given once daily as a subcutaneous injection in the same body areas, with rotation of the injection site. The study lasts for at least 52 weeks for primary outcomes, with cardiovascular events monitored for 104 weeks or more. During the study, participants will have regular assessments including blood tests for HbA1c, body weight measurements, waist circumference, blood pressure, cholesterol levels, and markers of inflammation. The main measure is the change in blood sugar control after 52 weeks. The study also tracks heart-related events and other health changes over two years. Participants will be monitored closely throughout the study period to evaluate safety and treatment effects.

Age: 45Years +All GendersPhase 3
330 locations
C

Actively Recruiting

Healthy Volunteer

Researchers are studying the Caris Biorepository, a project designed to collect and store high-quality biological specimens and related clinical data to support research aimed at advancing precision medicine and improving patient care. This observational study focuses on gathering samples and information from various sources, including healthy individuals and cancer patients, to help understand disease treatments and clinical outcomes. The biorepository includes samples from different donor groups, such as those with no disease, treatment-nave patients with new solid tumors, individuals at higher risk for cancer, patients with advanced cancer, and those with a history of cancer but no active disease. The project aims to maintain molecular integrity and clinical relevance of these specimens while providing access to researchers and collaborators for drug development, clinical trials, and healthcare policy enhancements. Participants provide informed consent and contribute biological samples and clinical data that are securely stored and shared for research purposes. The study measures include ensuring specimen quality and relevance over 35 years and facilitating specimen release for testing. Laboratory testing will be conducted throughout the study duration. The project supports long-term research collaboration and aims to impact patient outcomes and treatment practices over time.

Age: 18Years +All Genders
38 locations
E

Actively Recruiting

Researchers are evaluating how to best recommend chemotherapy for patients with colon cancer based on the presence or absence of circulating tumor DNA ctDNA after surgery. This Phase IIIII trial aims to determine if ctDNA can be used to better identify patients who need adjuvant chemotherapy and to assess optimal chemotherapy regimens for those with detectable ctDNA, as current biomarkers have not been prospectively validated. Participants are assigned to different groups based on their ctDNA status after surgery. Those without detectable ctDNA may undergo serial ctDNA monitoring without treatment or receive shorter chemotherapy regimens. Patients with detectable ctDNA receive more intensive chemotherapy options, including combinations of oxaliplatin, leucovorin, 5-fluorouracil, irinotecan, or capecitabine, administered intravenously or orally over cycles lasting several weeks. The study includes randomization and uses the Signatera test for central ctDNA detection. During the study, participants will undergo regular blood tests for ctDNA status, imaging scans, and clinical assessments. Researchers will track ctDNA positivity over up to 3 years and disease-free survival over up to 5 years. Other measures include overall survival, recurrence rates, and chemotherapy compliance. The total study duration may extend several years with ongoing monitoring to evaluate safety and treatment outcomes.

Age: 18Years +All GendersPhase 2Phase 3
1085 locations
S

Actively Recruiting

Researchers are conducting a combined phase 2b and phase 3 clinical trial to study CSL300 Clazakizumab in adults with end stage kidney disease ESKD who are undergoing maintenance dialysis. The study aims to find the right dose of CSL300 and then evaluate its effects on cardiovascular outcomes and safety in people with systemic inflammation and either atherosclerotic cardiovascular disease ASCVD or diabetes. This multicenter, randomized, double-blind, placebo-controlled trial is designed to provide detailed information on the drugs impact and risks. The study is divided into two parts. Part 1 phase 2b focuses on identifying the optimal dose of CSL300 compared to a placebo over 12 weeks. Part 2 phase 3 assesses the efficacy and safety of CSL300 versus placebo on cardiovascular events such as cardiovascular death or heart attack over approximately 5 years. Participants receive intravenous doses of CSL300 or placebo. The placebo matches the CSL300 product minus the active ingredient. Participants will be monitored through regular assessments including blood tests to measure markers of inflammation like high-sensitivity C-reactive protein hs-CRP, other blood components, and drug levels. The trial tracks cardiovascular events and safety outcomes over the study period. The research team will also observe changes in several blood markers related to inflammation and cardiovascular health. The total follow-up may last up to about five years to fully capture long-term effects and safety.

Age: 18Years +All GendersPhase 2Phase 3
566 locations
E

Actively Recruiting

Researchers are evaluating treatment options for younger patients with intermediate risk acute myeloid leukemia AML in this phase II trial. The study compares three different drug combinations cytarabine with daunorubicin cytarabine with daunorubicin plus venetoclax and venetoclax with azacitidine. The goal is to see if adding venetoclax improves the elimination of leukemia cells compared to the usual treatment, by measuring undetectable residual disease after therapy. Participants are randomly assigned to one of three treatment groups. One group receives daunorubicin and cytarabine with venetoclax over 28-day cycles, possibly followed by reinduction therapy based on bone marrow assessments. The second group receives azacitidine combined with venetoclax for two 28-day cycles. The third group receives daunorubicin and cytarabine alone, with potential reinduction treatment. Patients undergo bone marrow aspiration, blood sample collection, and heart function tests before and during the study. During the trial, participants will have regular evaluations including bone marrow tests and blood draws to monitor treatment effects and disease status. Heart function is assessed at screening with echocardiography or a MUGA scan. After completing treatment, patients are followed with visits at 4 weeks, every 3 months for the first year, every 6 months in the second year, and yearly thereafter. Researchers track remission rates, toxicities, survival outcomes, and responses based on genetic features for up to 10 years.

Age: 18Years - 59YearsAll GendersPhase 2
187 locations
E

Actively Recruiting

Healthy Volunteer

Researchers are evaluating two telephone-based symptom monitoring approaches to reduce symptom burden and psychological distress in people receiving oral anti-cancer treatment. The study compares interactive voice response IVR symptom monitoring alone to a combination of automated telephone symptom management ATSM with telephone interpersonal counseling TIPC. This research aims to improve symptom management and reduce interruptions in cancer therapy and unscheduled health services use. Participants are assigned to one of two groups. The first group receives weekly IVR calls for 12 weeks, where they report symptoms by phone, and summaries are sent to their providers. The second group receives the same IVR calls plus a Symptom Management and Survivorship handbook for self-management strategies. If patients in this group report anxiety or sadness over two weeks early in the study, they also receive up to eight weeks of telephone counseling focused on psychological distress and social support. During the study, participants complete weekly symptom calls for 12 weeks, followed by a 5-week follow-up period. Providers receive symptom reports to assist care. Researchers monitor symptom severity using patient-reported outcomes and track unscheduled health services use up to 17 weeks. Community oncology practice staff are assessed for implementation feasibility and acceptability of the interventions. Total participation may last over two years for some practice personnel assessments.

Age: 18Years +All GendersPhase Not Applicable
34 locations
E

Actively Recruiting

Healthy Volunteer

This research aims to understand how the Safe Dates for Young Parents SDYP program influences sexual and reproductive health behaviors, attitudes about healthy relationships, and intimate partner violence IPV prevention in adolescent and young adult females who are pregnant or parenting. Researchers want to see if the SDYP intervention changes these behaviors and beliefs compared to those who do not receive the program. Participants in the SDYP group will take part in ten 50-minute group sessions involving interactive discussions, role-plays, games, brainstorming, and creative activities like poster contests and theatrical plays. The control group will receive standard services such as case management and comprehensive sex education but without the IPV or healthy relationship content included in SDYP. Referrals to additional services will be available for all participants as needed. During the study, participants will complete interviews at three, six, and twelve months to assess sexual behaviors like condomless vaginal or anal sex, experiences of sexual and reproductive coercion, negotiation of contraception use, IPV occurrences, and attitudes toward healthy relationships. Researchers will monitor changes over time to evaluate the programs impact. The total participation lasts about one year, with ongoing contact information collection and verbal consent obtained for enrollment.

Age: 14Years - 21YearsFEMALEPhase Not Applicable
12 locations

1-10 of 25

1